[메디칼업저버 신형주 기자] JW Pharmaceutical’s new improved drug for dyslipidemia, Livarozet, surpassed KRW 100 billion in cumulative sales in about two years from its launch in October 2021 to December last year.
Rivarozet is a two-drug combination drug that combines pitavastatin and ezetimibe, ingredients for the treatment of dyslipidemia. It is Korea’s first new improved drug combining pitavastatin and ezetimibe among statins.
According to UBIST, Livarozet recorded sales of 31.8 billion won in 2022, soon after its launch, becoming a blockbuster.
Last year, it achieved sales of 70.4 billion won, more than double the previous year, and accumulated sales exceeded 100 billion won.
Notably, in December last year, it recorded a monthly revenue of KRW 6.9 billion, ranking third in the statin-ezetimibe combination drug market. As of January this year, cumulative sales amounted to 111.1 billion won.
Livarozet is recognized in the medical field not only for its effectiveness in reducing LDL cholesterol levels by approximately 54%, but also for the accumulated safety evidence against the recent problem of diabetes caused by the side effect of statins that increase levels of blood sugar.
Pitavastatin, the main ingredient in Livarozet, has been shown to be safe for new-onset diabetes mellitus (NODM), one of the typical side effects of statin ingredients.
The pharmaceutical product information (SmPC) of 32 countries worldwide for Livaro, a single pitavastatin medicine, includes the phrase “no signs of risk of developing diabetes”. This is unique in the statin family.
Last year, the first study was published in the international academic journal to verify the effectiveness of pitavastatin in primary prevention patients with cardiovascular disease accompanied by the human immunodeficiency virus (HIV), in which cardiovascular disease events occur approximately 50% more than the general population. ‘New England Journal’. of Medicine (NEJM).
As a result of the study, the incidence of cardiovascular events in the group of patients taking pitavastatin was significantly 35% lower than in the control group.
Furthermore, in a situation where human immunodeficiency virus patients need to pay attention to drug interactions when taking immunosuppressants, the advantage of pitavastatin in drug interactions was confirmed as the metabolic pathways do not overlap.
A JW Pharmaceutical official said: “Liva Roset has continued to grow and has established itself as a successful product based on various clinical data on efficacy and safety,” adding: “It has the advantage of minimizing various effects side effects as well as the effectiveness of lowering LDL cholesterol levels.” “On this basis we will continue to increase our market share,” he said.
#Cumulative #sales #exceeded #KRW #billion #years #Livarojet #launch
